Imidazoline receptors and their endogenous ligands

Annual Review of Pharmacology and Toxicology

Volumn 36, Issue , 1996, Pages 511-544

  Regunathan, S ^a   Reis, D J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

agmatine; clonidine; clonidine displacing substance; idazoxan; mitochondria

Indexed keywords

AGMATINE; APRACLONIDINE; CIRAZOLINE; CLONIDINE; EFAROXAN; GUANABENZ; IDAZOXAN; IMIDAZOLINE RECEPTOR; LIGAND; LOFEXIDINE; MOXONIDINE; RECEPTOR PROTEIN; RILMENIDINE;

BINDING SITE; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW;

EID: 0029891613     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.36.040196.002455     Document Type: Review

References (170)

1. Ruffolo RR, Waddell JEW. 1982. Receptor interactions of imidazolines: α-adrenoceptors of rat and rabbit aortae differentiated by relative potencies, affinities and efficacies of imidazoline agonists. Br. J. Pharmacol. 77:169-76
2. Ruffolo RR, Turowski BS, Patil PN. 1977. Lack of cross-desensitization between structurally dissimilar α-adrenoceptor agonists. J. Pharm. Pharmacol. 29:378-80
3. 2-adrenergic effects of phenethylamines and imidazolines. Eur. J. Pharmacol. 86:471-75
4. Karppanen H, Paakkari I, Paakkari P, Huotari R, Orma AL. 1976. Possible involvement of central histamine H2-receptors in the hypotensive effect of clonidine. Nature 259:587-88
5. Petrusewicz J, Kaliszan R. 1986. Blood platelet adrenoceptor: aggregatory and antiaggregatory activity of imidazoline drugs. Pharmacology 33:249-55
6. Bemardini C, Del Tacca M, Soldani G, Martinotti E. 1986. The effects of alpha-2 agonists and antagonists on gastric acid secretion. Arch. Int. Pharmacodyn. Ther. 281:134-44
7. Bousquet P, Feldman J, Schwartz J. 1984. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230:232-36
8. Reis DJ. 1995. Neurons and receptors in the rostral ventrolateral medulla mediating the antihypertensive actions of "imidazoline" drugs. J. Cardiovasc. Pharmacol. In press
9. Ernsberger P, Meeley MP, Mann JJ, Reis DJ. 1987. Clonidine binds to imidazole binding sites as well as alpha2-adrenoceptors in the ventrolateral medulla. Eur. J. Pharmacol. 134:1-13
10. 3H-idazoxan in rat brain. J. Pharmacol. Exp. Ther. 241: 1079-91
11. Wikberg JE. 1989. High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: description of a putative idazoxan-receptor. Pharmacol. Toxicol. 64: 152-55
12. Coupry I, Podevin RA, Dausse JP, Parini A. 1987. Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney. Biochem. Biophys. Res. Commun. 147:1055-60
13. Brown CM, MacKinnon AC, McGrath JC, Spedding M, Kilpatrick AT. 1990. Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain. Br. J. Pharmacol. 99:803-9
14. De Vos H, Bricca G, De Keyser J, De Backer JP, Bousquet P, Vauquelin G. 1994. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. Neuroscience 59:589-98
15. Regunathan S, Meeley MP, Reis DJ. 1993. Expression of non-adrenergic imidazoline sites in chromaffin cells and mitochondrial membranes of bovine adrenal medulla. Biochem. Pharmacol. 45: 1667-75
16. 3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site. Mol. Pharmacol. 35:324-30
17. Zonnenchein R, Diamant S, Atlas D. 1990. Imidazoline receptors in rat liver cells: a novel receptor or a subtype of alpha 2-adrenoceptors? Eur. J. Pharmacol. 190:203-15
18. 3H]-idazoxan binds with high affinity to two sites on hamster adipocytes: an alpha 2-adrenoceptor and a non-adrenoceptor site. Br. J. Pharmacol. 98:1143-50
19. 3H]idazoxan binding at non-alpha 2-adrenoceptors in rabbit adipocyte membranes. Eur. J. Pharmacol. 159:199-203
20. 3H]idazoxan in the smooth muscle of rabbit urethra. Eur. J. Pharmacol. 154:209-12
21. Senard JM, Langin D, Estan L, Paris H. 1990. Identification of alpha 2-adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cells. Eur. J. Pharmacol. 191: 59-68
22. 2-sites. Br. J. Pharmacol. 112: 1065-70
23. Wikberg JE, Uhlen S. 1990. Further characterization of the guinea pig cerebral cortex idazoxan receptor: Solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor-selective drug. J. Neurochem. 55:192-203
24. Atlas D. 1991. Clonidine-displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of alpha 2-adrenergic receptor activity. Biochem. Pharmacol. 41: 1541-49
25. Bricca G, Dontenwill M, Molines A, Feldman J, Belcoun A, Bousquet P. 1989. The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur. J. Pharmacol. 162:1-9
26. Coupry I, Atlas D, Podevin RA, Uzielli I, Parini A. 1990. Imidazoline-guanidinium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance. J. Pharmacol. Exp. Ther. 252:293-99
27. Michel MC, Ernsberger P. 1992. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol. Sci. 13:369-70
28. 3H]idazoxan in the human cerebral cortex. Neurochem. Int. 22:153-63
29. Reis DJ, Regunathan S, Meeley MP. 1992. Imidazole receptors and clonidine-displacing substance in relationship to control blood pressure, neuroprotection and adrenomedullary secretion. Am. J. Hypertens. 5:S51-S57
30. 1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann. NY Acad. Sci. 763:22-42
31. Ernsberger P, Giuliano R, Willette RN, Reis DJ. 1990. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J. Pharmacol. Exp. Ther. 253:408-18
32. 1-imidazoline sites. J. Pharmacol. Exp. Ther. 264:172-82
33. 3H]-p-aminoclonidine to alpha 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes. Biochem. Pharmacol. 42:569-84
34. 3H]clonidine. Eur. J. Pharmacol. 266:25-33
35. Hamilton CA, Yakubu MA, Jardine E, Reid JL. 1991. Imidazole binding sites in rabbit kidney and forebrain membranes. J. Auton. Pharmacol. 11:277-83
36. 2-receptors. Ann. NY Acad. Sci. 763: 43-56
37. 3H]idazoxan label different populations of imidazoline sites on rat kidney. Eur. J. Pharmacol. 232:79-87
38. Piletz JE, Sletten K. 1993. Nonadrenergic imidazoline binding sites on human platelets. J. Pharmacol. Exp. Ther. 267:1493-502
39. Tesson F, Prip-Buus C, Lemoine A, Pegorier JP, Parini A. 1992. Characterization of mitochondrial imidazoline-guanidinium receptive sites (IGRS) in liver. Am. J. Hypertens. 5:S80-S82
40. 1-imidazoline sites in bovine adrenal medullary membranes. Naunyn Schmiedebergs Arch. Pharmacol. 348:70-76
41. Regunathan S, Evinger MJ, Meeley MP, Reis DJ. 1991. Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells. Biochem. Pharmacol. 42: 2011-18
42. 1 agents: a new approach to the treatment of hypertension. Ann. NY Acad. Sci. 763:642-58
43. Laragh JH. 1995. Rilmenidine and the high risk hypertensive patient. Ann. NY Acad Sci. 763:634-41
44. 3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain. Brain Res. 514:15-21
45. 2-adrenoceptor agonist and clorudine in conscious spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 16:837-48
46. 2-agonist binding sites in the rat and human central nervous system: analysis of functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res. Rev. 7:69-101
47. Punnen S, Urbanski R, Krieger AJ, Sapru HN. 1987. Ventrolateral medullary pressor area: site of hypotensive action of clonidine. Brain Res. 422:336-46
48. Head GA. 1995. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents. Ann. NY Acad. Sci. 763: 531-40
49. Sannajust F, Head GA. 1994. Involvement of imidazoline-preferring receptors in regulation of sympathetic tone. Am. J. Cardiol. 74:A7-A19
50. 2-adrenergic recptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 273:1162-71
51. 1-imidazoline agonist. Cardiovasc. Drugs Ther. 8(Suppl. 1):27-41
52. Hieble JP, Kolpak DC. 1993. Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors. Br. J. Pharmacol. 110:1635-39
53. 2-adrenoceptors or imidazoline receptors? J. Pharmacol. Exp. Ther. 270(2):572-78
54. Szabo B, Urban R. 1995. Mechanism of sympathoinhibition by imidazolines. Ann. NY Acad. Sci. 763:552-65
55. Allen AM, Guyenet PG. 1993. Alpha 2-adrenoceptor-mediated inhibition of bulbospinal barosensitive cells of rat rostral medulla. Am. J. Physiol. 265: R1065-75
56. Stornetta RL, Huangfu D, Rosin DL, Lynch KR, Guyenet PG. 1995. Alpha-2 adrenergic receptors: Immunohistochemical localization and role in mediating inhibition of adrenergic RVLM presympathetic neurons by catecholamines and clonidine. Ann. NY Acad. Sci. 763:541-51
57. Reis DJ, Golanov EV, Ruggiero DA, Sun M-K. 1994. Sympatho-excitatory neurons of the rostral medulla are oxygen sensors and essential elements in the tonic and reflex control of the systemic and cerebral circulations. J. Hypertens. 12:5159-80 (Suppl.)
58. Tingley FD 3d, Arneric SP. 1990. Evidence for clonidine presynaptically modulating amino acid release in the rostral ventral medulla: role in hypertension. Brain Res. 537:175-81
59. Sun M-K, Reis DJ. 1995. GABA-mediated inhibition of pacemaker neurons of rostral ventrolateral medulla by clonidine in vitro. Eur. J. Pharmacol. 276: 291-96
60. Schäfer SG, Kaan EC, Christen MO, Löw-Kröger A, Mest H-J, Molderings G-J. 1995. Why imidazoline receptor modulator in the treatment of hypertension? Ann. NY Acad. Sci. 763:659-72
61. Gomez RE, Ernsberger P, Feinland G, Reis DJ. 1991. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Eur. J. Pharmacol. 195:181-91
62. Allan DR, Penner SB, Smyth DD. 1993. Renal imidazoline preferring sites and solute excretion in the rat. Br. J. Pharmacol. 108:870-75
63. 1 imidazoline receptor agonist, moxonidine. Br. J. Pharmacol. 112:1089-94
64. Evinger MJ, Ernsberger P, Regunathan S, Reis DJ. 1995. Regulation of PNMT gene expression by imidazoline receptors in adrenal chromaffin cells. J. Neurochem 65:988-97
65. Felsen D, Ernsberger P, Sutaria PM, Nejat RJ, Nguyen P, et al. 1994. Identification, localization and functional analysis of imidazoline and alpha adrenergic receptors in canine prostate. J. Pharmacol. Exp. Ther. 268:1063-71
66. 1) receptors in modulating aqueous humor dynamics. J. Ocul. Pharmacol. 10:393-402
67. Romanovsky AA, Shido O, Ungar AL, Blatteis CM. 1993. Genesis of biphasic thermal response to intrepreoptically microinjected clonidine. Brain Res. Bull. 31:509-13
68. 1-imidazoline receptors in mood disorders. Ann. NY Acad. Sci. 763:510-19
69. 2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch. Gen. Psychiatry 46: 958-59
70. Lachaud-Pettiti V, Podevin RA, Chretien Y, Parini A. 1991. Imidazoline-guanidinium and alpha 2-adrenergic binding sites in basolateral membranes from human kidney. Eur. J. Pharmacol. 206:23-31
71. 3H] RX821002 labels additional non-alpha 2-adrenergic binding sites. Mol. Pharmacol. 37:876-85
72. 3H]RX8-21002 (2-methoxy idazoxan) in the human and rat brains. J. Pharmacol. Exp. Ther. 264:1187-97
73. 3H] idazoxan binding sites (I-receptors) occurs to interacting or interconvertible affinity forms of the receptor. Pharmacol. Toxicol. 70:208-19
74. Regunathan S, Feinstein DL, Reis DJ. 1993. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J. Neurosci. Res. 34:681-88
75. 2-imidazoline sites. Naunyn Schmiedebergs Arch. Pharmacol. 350:252-57
76. Diamant S, Eldar-Geva T, Atlas D. 1992. Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function. Br. J. Pharmacol. 106:101-8
77. 3H]idazoxan in the rabbit urethral smooth muscle. Pharmacological and biochemical characterization. Biochem. Pharmacol. 41:701-7
78. Lacombe C, Viallard V, Paris H. 1993. Identification of alpha 2-adrenoceptors and of non-adrenergic idazoxan binding sites in pancreatic islets from young and adult hamsters. Int. J. Biochem. 25: 1077-83
79. 2 sites. Ann. NY Acad. Sci. 763:153-56
80. 2-imidazoline receptors in rat prostate and regulation by testosterone. Biochem. Pharmacol. In press
81. Youngson C, Regunathan S, Wang H, Li G, Reis DJ. 1995. Co-expression of imidazoline receptors and agmatine in rat carotid body. Ann. NY Acad. Sci. 763:440-44
82. Regunathan S, Youngson C, Raasch W, Wang H, Reis DJ. 1995. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. J. Pharmacol. Exp. Ther. In press
83. Limon I, Coupry I, Larder SM, Parini A. 1992. Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney. J. Biol. Chem. 267:21645-49
84. Tesson F, Parini A. 1991. Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. Eur. J. Pharmacol. 208: 81-83
85. Tesson F, Prip-Buus C, Lemoine A, Pegorier JP, Parini A. 1991. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. J. Biol. Chem. 266:155-60
86. Tesson F, Limon I, Parini A. 1992. Tissue-specific localization of mitochondrial imidazoline-guanidinium receptive sites. Eur. J. Pharmacol. 219: 335-38
87. + transport and intracellular pH in renal proximal tubule cells. Biochim. Biophys. Acta 1024:173-78
88. Dunne MJ. 1991. Block of ATP-regulated potassium channels by phentolamine and other alpha-adrenoceptor antagonists. Br. J. Pharmacol. 103: 1847-50
89. Ibbotson T, Edwards G, Weston AH. 1993. Antagonism of levcromakalim by imidazoline- and guanidine-derivatives in rat portal vein: involvement of the delayed rectifier. Br. J. Pharmacol. 110: 1556-64
90. Okumura K, Ichihara K, Nagasaka M. 1992. Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein. Eur. J. Pharmacol. 215:253-57
91. + currents in Xenopus oocytes. Eur. J. Pharmacol. 259:223-31
92. Maiese K, Pek L, Berger SB, Reis DJ. 1992. Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J. Cereb. Blood Flow Metab. 12:53-63
93. Gustafson I, Westerberg E, Wieloch T. 1990. Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: Influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab. 10:885-94
94. Jackson HC, Griffin IJ, Nutt DJ. 1991. The effects of idazoxan and other ctzadrenoceptor antagonists on food and water intake in the rat. Br. J. Pharmacol. 104:258-62
95. Jackson HC, Nutt DJ. 1992. Are 5-HT receptors or beta-adrenoceptors involved in idazoxan-induced food and water intake? Neuropharmacology 31: 1081-87
96. Moldenngs GJ, Hentrich F, Göthert M. 1991. Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery. Naunyn Schmiedebergs Arch. Pharmacol. 344:630-38
97. 2-imidazoline binding sites. Naunyn Schmiedebergs Arch. Pharmacol. 351:507-16
98. Göthert M, Molderings GJ. 1991. Involvement of presynaptic imidazoline receptors in the alpha 2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives. Naunyn Schmiedebergs Arch. Pharmacol. 343:271-82
99. Chan SL, Morgan NG 1990. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur. J. Pharmacol. 176:97-101
100. Olmos G, Alemany R, Escriba PV, Garcia-Sevilla JA. 1994. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br. J. Pharmacol. 111:997-1002
101. Hamilton CA, Jardine E, Reid JL. 1993. Down-regulation of imidazoline sites in rabbit kidney. Eur. J Pharmacol. 243: 95-97
102. Hamilton CA. 1995. Imidazoline receptors, subclassificatjon, and drug-induced regulation. Ann. NY Acad. Sci. 763:57-65
103. Olmos G, Miralles A, Barturen F, Garcia-Sevilla JA. 1991. Repeated idazoxan increases brain imidazoline receptors in normotensive (WKY) but not in hypertensive (SHR) rats. J. Neurochem. 57: 1811-13
104. Olmos G, Miralles A, Barturen F, Garcia-Sevilla JA. 1992. Characterization of brain imidazoline receptors in normotensive and hypertensive rats: differential regulation by chronic imidazoline drug treatment. J. Pharmacol. Exp. Ther. 260:1000-7
105. 3H]-idazoxan binding sites in the rat brain. Br. J. Pharmacol. 108:597-603
106. 2 sites. J. Pharmacol. Exp. Ther. 272:681-88
107. 2-imidazoline binding sites on monoamine oxidases. J. Biol. Chem. 270:9856-61
108. 2 with monoamine oxidase-β sites. J. Neurochem. 61:881-89
109. 2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neurosci. Lett. 160:109-12
110. 3H]idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol. Psychiatry 34: 498-501
111. Escriba PV, Sastre M, Wang H, Regunathan S, Reis DJ, Garcia-Sevilla JA. 1994. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci. Lett. 178:81-84
112. 3H]rilmenidine binding to membranes of rat cerebral cortex. Am. J. Hypertens. 5.S64-S68
113. 3H]Cirazoline as a tool for the characterization of imidazoline sites. Ann. NY Acad. Sci. 763:112-24
114. 3H]atipamezole in rat lung. A novel imidazole binding site? Ann. NY Acad. Sci. 763: 66-77
115. Brown CA, Morgan NG. 1993. Control of insulin secretion by imidazolines in rat pancreatic islets. Biochem. Soc. Trans. 21:S109
116. Brown CA, Loweth AC, Smith SA, Morgan NG. 1993. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. Br. J. Pharmacol. 108:312-17
117. 3H]idazoxan binding sites are physically distinct from alpha 2-adrenergic receptors. Mol. Pnarmacol. 37:65-68
118. 2-adrenergic receptor. J. Biol. Chem. 264:11874-78
119. Wang H, Regunathan S, Meeley MP, Reis DJ. 1992. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells. Mol. Pharmacol. 42:792-801
120. Wang H, Regunathan S, Ruggiero DA, Reis DJ. 1993. Production and characterization of antibodies specific for the imidazoline receptor protein. Mol. Pharmacol. 43:509-15
121. Fatima B, Hugues G, Giampiero B, Alain B, Pascal B, Dontenwill M. 1993. Polyclonal anti-idazoxan antibodies: characterization and purification. Eur. J. Pharmacol. 246:45-51
122. 3H]clonidine. Neurochem. Int. 25:183-91
123. Lamer SM, Ivkovic B, Singh I, Neumeyer JL, Bakthavachalam V. 1993. Visualization of multiple imidazoline/ guanidinium-receptive sites. J Biol. Chem. 268:16047-51
124. Mallard NJ, Hudson AL, Nutt DJ. 1992. Characterization and autoradiographjcal localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br. J. Pharmacol. 106:1019-27
125. Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ. 1995. Distribution of imidazoline receptor binding protein in the central nervous system. Ann. NY Acad. Sci. 763:208-21
126. 2-adrenergic receptor subtypes in rat brain: an in situ hybridization study. J. Comp. Neurol. 328:575-94
127. Atlas D, Burstein Y. 1984. Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur. J. Biochem. 144:287-93
128. Meeley MP, Ernsberger PR, Granata AR, Reis DJ. 1986. An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci. 38:1119-26
129. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. 1994. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263:966-69
130. Atlas D, Burstein Y. 1984. Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS Lett. 170:387-90
131. Ernsberger P, Meeley MP, Reis DJ. 1988. An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medulla. Brain Res. 441:309-18
132. Regunathan S, Meeley MP, Reis DJ. 1991. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. Mol. Pharmacol. 40:884-88
133. Synetos D, Manolopoulos VG, Atlas D, Pipili-Synetos E. 1991. Human plasmaderived material with clonidine displacing substance (CDS)-like properties contracts the isolated rat aorta. J. Auton. Pharmacol. 11:343-51
134. Goldberg-Stern H, Atlas D, Schwartz L. Achiron A, Ziv I, et al. 1993. Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid. Brain Res. 601:325-28
135. Reis DJ, Li G, Regunathan S. 1995. Endogenous ligands of imidazoline receptors: classic and immunoreactive clonidine-displacing substance and agmatine. Ann. NY Acad. Sci. 763:295-313
136. 2-adrenoceptors of human platelets. Eur. J. Pharmacol. 144:247-55
137. Diamant S, Atlas D. 1986. An endogenous brain substance, CDS (clonidine-displacing-substance), inhibits the twitch response of rat vas deferons. Biochem. Biophys. Res. Commun. 134: 184-90
138. Felsen D, Ernsberger P, Meeley MP, Rets DJ. 1987. Clonidine displacing substance is biologically active on smooth muscle. Eur. J. Pharmacol. 142: 453-55
139. Bousquet P, Feldman J, Atlas D. 1986. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur. J. Pharmacol. 124: 167-70
140. Kreisberg GA, Diamant S, Diamant YZ, Atlas D. 1987. Raised levels of an endogenous nonadrenergic substance in the serum of pregnancy-induced hypertension patients. Isr. J. Med. Sci. 23: 1194-97
141. Meeley MP, Towle AC, Char LK, Ernsberger P, Reis DJ. 1986. Polyclonal antiserum to a para-aminoclonidine conjugate recognizes an endogenous clonidine-like substance(s) in brain. Soc. Neurosci. Abstr. 12:963
142. Meeley MP, Towle AC, Ernsberger P, Char LK, McCauley PM, Reis DJ. 1989. Clonidine-specific antisera recognize an endogenous clonidine-displacing substance in brain. Hypertension 13:341-51
143. Dontenwill M, Bricca G, Molines A, Bousquet P, Belcourt A. 1988. Production and characterization of anti-clonidine antibodies not cross-reacting with catecholamines. Eur. J. Pharmacol. 149: 249-55
144. Dontenwill M, Molines A, Bricca G, Stutzman J, Kempf J, et al. 1992. Production and characterization of an iminoimidazolidine specific monoclonal antibody using para-aminoclonidine as antigen. Life Sci. 50:1859-68
145. Meeley MP, Hensley ML, Ernsberger P, Felsen D, Reis DJ. 1992. Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum. Biochem. Pharmacol. 44:733-40
146. 145b. Dontenwill M, Molines A, Verdun A, Bricca G, Laurent S, Bousquet P. 1993. A circulating substance cross-reacting with antiimidazoline antibodies. Detection in serum in relation to essential hypertension. J. Clin. Invest. 92:1068-72
147. Raasch W, Regunathan S, Li G, Reis DJ 1995 Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci. 56:2319-30
148. Wang H, Regunathan S, Youngson C, Reis DJ. 1995. An antibody to agmatine localizes the amine in bovine adrenal chromaffin cells. Neurosci. Lett. 183:1-5
149. Regunathan S, Feinstein DL, Raasch W, Reis DJ. 1995. Agmatine, the decarboxylated arginine, is localized and synthesized in glial cells. NeuroReport 6: 1897-900
150. Wang H, Otake K, Ruggiero DA, Milner TA, Li G, et al. 1994. Regional distribution of agmatine and arginine decarboxylase in rat brain. Soc. Neurosci. Abstr. 20:1060
151. Tabor CW, Tabor H. 1984. Polyamines. Annu. Rev. Biochem. 53:749-90
152. Li G, Regunathan S, Reis DJ. 1995. Agmatine is synthesized by a mitochondrial arginine decarboxylase in rat brain. Ann. NY Acad. Sci. 763:325-29
153. Buch JK, Boyle SM. 1985. Biosynthetic arginine decarboxylase in Escherichia coli is synthesized as a precursor and located in the cell envelope. J. Bacteriol. 163:522-27
154. Yakubu MA, Basso B, Kierszenbaum F. 1992. D1-alpha-difluoromethylarginine inhibits intracellular Trypanosoma cruzi multiplication by affecting cell division but not trypomastigote-amastigote transformation. J. Parasitol. 78:414-19
155. Schaeffer JM, Donatelli MR. 1990. Characterization of a high-affinity membrane-associated ornithine decarboxylase from the free-living nematode Caenorhabditis elegans. Biochem. J. 270:599-604
156. Quik M. 1985. Inhibition of nicotinic receptor mediated ion fluxes in rat sympathetic ganglia by bgt ii-sl a potent phospholipase. Brain Res. 325:79-88
157. Kuzirian A, Meyhofer E, Hill L, Neary JT, Alkon DL. 1986. Autoradiographic measurement of tritiated agmatine as an indicator of physiologic activity in Hermissenda visual and vestibular neurons. J. Neurocytol. 15:629-43
158. 157a. Loring RH. 1990. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br. J. Pharmacol. 99:207-11
159. 2-adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 351:10-16
160. Sener A, Lebrun P, Blachier F, Malaisse WJ. 1989. Stimulus-secretion coupling of arginine-induced insulin release: insulinotropic action of agmatine. Biochem. Pharmacol. 38:327-30
161. Weitzel G, Pfeiffer B, Stock W. 1980. Insulin-like partial effects of agmaline derivatives in adipocytes. Hoppe Seylers. Z. Physiol. Chem. 361:51-60
162. Sun M-K, Regunathan S, Reis DJ. 1995. Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rats. Clin. Exp. Hypertens. 17:115-28
163. Szabo B, Urban R, Limberger N, Starke K. 1995. Cardiovascular effects of agmatine, a "clonidine-displacing substance", in conscious rabbits. Naunyn-Schmiedebergs Arch. Pharmacol. 351:268-73
164. Kalra SP, Pearson E, Sahu A, Kalra PS. 1995. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothaiamic luteinizing hormone-releasing hormone release in vitro. Neurosci. Lett. 194:165-68
165. Kolesnikov Y, Jain S, Pasternak GW. 1995. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. In press
166. Glavin GB, Carlisle MA, Smyth DD. 1995. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric roucosal injury in rats. J. Pharmacol. Exp. Ther. 274:741-44
167. Sastre M, Regunathan S, Reis DJ. 1995. Enzymatic hydrolysis of agmatine to putrescine in rat brain. Soc. Neurosci. Abstr. 21:810-15
168. Reis DJ, Bousquet P, Parini A, eds. 1995. The Imidazoline Receptor: Pharmacology, Functions Ligands, and Relevance to Biology and Medicine, Vol. 763. New York: NY Acad. Sci. 707 pp.
169. Bylund DB. 1995. Pharmacological characteristics of alpha-2 adrenergic receptor subtypes. Ann. NY Acad. Sci. 763:1-7
170. Piletz JE, Chikkala DN, Ernsberger P. 1995. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J. Pharmacol. Exp. Ther. 272: 581-87